Advanced proteomics procedure as a detection tool for predictive screening in type 2 pre-diabetes

EPMA Journal

Volumn 1, Issue 1, 2010, Pages 19-31

  Koehn, Jadranka ^a   Krapfenbauer, Kurt ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Beta cell failure; Diabetes mellitus; Glycotoxicity; Lipotoxicity; Pancreatic polypeptide y; Predictive biomarker; Proteomics

Indexed keywords

ABC TRANSPORTER A1; ACARBOSE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; HLA DQ ANTIGEN; INSULIN; INTERLEUKIN 6; LEPTIN; METFORMIN; PANCREAS ISLET CELL ANTIBODY; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE IA 2; REPAGLINIDE; SEX HORMONE BINDING PROTEIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ABCA1 GENE; CELL DIFFERENTIATION; COMPUTER MODEL; CTLA4 GENE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE MODEL; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; GENE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HLA DQ GENE; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TREATMENT PLANNING; UNINDEXED SEQUENCE;

EID: 79960045146     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0005-6     Document Type: Review

References (55)

1. Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222-234.
2. Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem. 2001;47:1985-1992.
3. Landin-Olsson M, Nilsson KO, Lernmark A, et al. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia. 1990;33:561-568.
4. Meier C, Ladewig A, Keller U, et al. Clinical value of C-peptide determination. Praxis. 1997;86:1289-1295.
5. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48:436-472.
6. Koehn J, Fountoulakis M, Krapfenbauer K. Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance. Infect Disord Drug Targets. 2008;8:109-118.
7. Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia. 2008;51:926-940.
8. Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913-2918.
9. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. Jama. 2006;295:1288-1299.
10. Smirnakis KV, Plati A, Wolf M, et al. Predicting gestational diabetes: choosing the optimal early serum marker. Am J Obstet Gynecol. 2007;196(410):e411-416. discussion 410 e416-7.
11. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001;286:327-334.
12. Kaye TB, Guay AT, Simonson DC. Non-insulin-dependent diabetes mellitus and elevated serum ferritin level. J Diabetes Complications. 1993;7:246-9.
13. Eshed I, Elis A, Lishner M. Plasma ferritin and type 2 diabetes mellitus: a critical review. Endocr Res. 2001;27:91-97.
14. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226-228.
15. Vasseur F, Lepretre F, Lacquemant C, et al. The genetics of adiponectin. Curr Diab Rep. 2003;3:151-158.
16. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762-9.
17. Schmidt MI, Duncan BB, Vigo A, et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006;49:2086-2096.
18. Festa A, D'Agostino Jr R, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-1137.
19. Eliasson MC, Jansson JH, Lindahl B, et al. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol. 2003;2:19.
20. Wannamethee SG, Sattar N, Rumley A, et al. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care. 2008;31:995-1000.
21. Meigs JB, O'Donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006;55:530-537.
22. Jacqueminet S, Briaud I, Rouault C, et al. Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration. Metabolism. 2000;49:532-536.
23. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes. 1999;48:738-744.
24. Shafrir E, Ziv E, Mosthaf L. Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models. Ann N Y Acad Sci. 1999;892:223-246.
25. Anello M, Rabuazzo AM, Degano C, et al. Fast reversibility of glucose-induced desensitization in rat pancreatic islets. Evidence for an involvement of ionic fluxes. Diabetes. 1996;45:502-506.
26. Marshak S, Leibowitz G, Bertuzzi F, et al. Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes. 1999;48:1230-1236.
27. Busch AK, Cordery D, Denyer GS, et al. Expression profiling of palmitate-and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic beta-cell function. Diabetes. 2002;51:977-987.
28. Carlsson C, Borg LA, Welsh N. Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology. 1999;140:3422-3428.
29. Shimabukuro M, Zhou YT, Levi M, et al. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A. 1998;95:2498-2502.
30. Mandrup-Poulsen T. beta-cell apoptosis: stimuli and signaling. Diabetes. 2001;50 Suppl 1:S58-63.
31. Asfari M, Janjic D, Meda P, et al. Establishment of 2- mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology. 1992;130:167-178.
32. Miyazaki J, Araki K, Yamato E, et al. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology. 1990;127:126-132.
33. Praz GA, Halban PA, Wollheim CB, et al. Regulation of immunoreactive-insulin release from a rat cell line (RINm5F). Biochem J. 1983;210:345-352.
34. Karlsson K, Cairns N, Lubec G, et al. Enrichment of human brain proteins by heparin chromatography. Electrophoresis. 1999;20:2970-2976.
35. Shin JH, Krapfenbauer K, Lubec G. Large-scale identification of cytosolic mouse brain proteins by chromatographic prefractionation. Electrophoresis. 2006;27:2799-2813.
36. Conrad EH. Heparin-binding proteins. San Diego: Academic Press, Inc.; 1998.
37. Pollak D, Krapfenbauer K, Fountoulakis M, et al. Expressional pattern of known and predicted signaling proteins in seven human cell lines. J Chromatogr. 2004;808:185-208.
38. Shin JH, Krapfenbauer K, Lubec G. Column chromatographic prefractionation leads to thedetectionof543differentgeneproducts in human fetal brain. Electrophoresis. 2005;26:2759-2778.
39. Cagney G, Park S, Chung C, et al. Human tissue profiling with multidimensional protein identification technology. J Proteome Res. 2005;4:1757-1767.
40. Florens L, Washburn MP. Proteomic analysis by multidimensional protein identification technology. Methods in molecular biology Clifton, NJ, 328, 159-175. 2006.
41. Fountoulakis M, Juranville JF, Jiang L, et al. Depletion of the high-abundance plasma proteins. Amino acids. 2004;27:249-259.
42. Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog Neurobiol. 2003;69:193-211.
43. Koehn J, Turhani D, Krapfenbauer K. Potential predictive biomarkers for the dysfunction of beta-cells in type 2 diabetes In: Golubnitschaja O (ed) Predictive Diagnostics and personalized Treatment, Dream or Reality? Nova Publisher. 2009.
44. Fountoulakis M, Langen H. Identification of proteins by matrixassisted laser desorption ionization-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. Anal Biochem. 1997;250:153-156.
45. Peyrl A, Krapfenbauer K, Slavc I, et al. Protein profiles of medulloblastoma cell lines DAOY and D283: identification of tumor-related proteins and principles. Proteomics. 2003;3:1781-1800.
46. Langen H, Roder D, Juranville JF, et al. Effect of protein application mode and acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis. 1997;18:2085-2090.
47. Wang F, Permet J, Ostenson CG. Islet amyloid polypeptide regulates multible steps in stimulus-secretion coupling of beta cells in rat pancreatic islets. Pancreas. 2000;20(3):264-269.
48. Karlsson E, Stridsberg M, Sandler S. Leptin regulation of islet amyloid polypeptide secretion from mouse pancreatic islets. Biochem Pharmcol. 1998;15(56(10)):1339-1346.
49. Golubnitschaja O, Flammer J. What are the biomarkers for glaucoma? Surv Ophthalmol. 2007;52 Suppl 2:S155-161.
50. Golubnitschaja O, Yeghiazaryan K, Wunderlich K, et al. Disease proteomics reveals altered basic gene expression regulation in leukocytes of Normal-Tension and Primary Open-Angle glaucoma patients. Proteomics Clin Appl. 2007;1:1316-1323.
51. Clark A. Islet amyloid and type 2 diabetes. Diabet Med. 1989;6:561-567.
52. Nishi M, Sanke T, Nagamatsu S, et al. Islet amyloid polypeptide. A new beta cell secretory product related to islet amyloid deposits. J Biol Chem. 1990;265:4173-4176.
53. Westermark P, Wernstedt C, Wilander E, et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A. 1987;84:3881-3885.
54. Ohsawa H, Kanatsuka A, Yamaguchi T, et al. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun. 1989;160:961-967.
55. Howard Jr CF. Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia. 1986;29:301-306.